Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
In: Blood, Jg. 140 (2022-11-15), S. 557-560
Online
unknown
Zugriff:
Titel: |
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
|
---|---|
Autor/in / Beteiligte Person: | Palomba, M.Lia ; Patel, Manish R. ; Eyre, Toby A. ; Jurczak, Wojciech ; David John Lewis ; Gastinne, Thomas ; Ma, Shuo ; Cohen, Jonathon B. ; Patel, Krish ; Brown, Jennifer R. ; Scarfò, Lydia ; Munir, Talha ; Lech-Marańda, Ewa ; Hoffmann, Marc ; Ujjani, Chaitra S. ; Fakhri, Bita ; Wang, Michael L. ; Izutsu, Koji ; Nagai, Hirokazu ; Tam, Constantine S. ; Seymour, John F. ; Rhodes, Joanna M. ; Vose, Julie M. ; McKinney, Matthew ; Gerson, James N. ; Barve, Minal A. ; Kuss, Bryone J. ; Koh, Youngil ; Gao, Wei ; Ruppert, Amy S. ; Walgren, Richard A. ; Tsai, Donald E. ; Nair, Binoj ; Bao, Katherine ; Mato, Anthony R. ; Cheah, Chan Y. |
Link: | |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), S. 557-560 |
Veröffentlichung: | American Society of Hematology, 2022 |
Medientyp: | unknown |
ISSN: | 1528-0020 (print) ; 0006-4971 (print) |
DOI: | 10.1182/blood-2022-159123 |
Schlagwort: |
|
Sonstiges: |
|